Get the Stockscreener App
0.00
100.00%
-6.75
After Hours:
6.95
6.95
+
Athira Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$6.75
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$26.62M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
0.00
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$8.36
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.00 | 26.62M | 0 | -117.67M | -101.06M | -3.09 |
VRTX
Vertex Pharmaceuticals Inc
|
425.00 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.10 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
787.31 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.91 | 40.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
317.00 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-19-26 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
LeonaBio (LONA) director receives 56,000 stock options at $9.63 strike - Stock Titan
Director at LeonaBio (LONA) granted 56,000 stock options - Stock Titan
Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63 - Stock Titan
Natalie Holles named LeonaBio (LONA) director in initial Form 3 - Stock Titan
LeonaBio (LONA) director Peter B. Silverman files initial Form 3 - Stock Titan
LeonaBio (LONA) director Callori Fred files baseline Form 3 ownership report - Stock Titan
Perceptive Advisors (ATHA) caps LeonaBio stake at 19.99% and gains board seat - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
Athira Pharma (LONA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LONA - MarketBeat
Independent Nonclinical Research on Lasofoxifene Presented - GlobeNewswire
LeonaBio CEO Litton sells $27,687 in shares - Investing.com
Athira Pharma (NASDAQ:LONA) Shares Down 6.5%Should You Sell? - MarketBeat
28,000-share stock option grant to LeonaBio (LONA) director - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to chief scientific officer - Stock Titan
28,000 stock options granted to LeonaBio (LONA) director Kosacz - Stock Titan
LeonaBio (LONA) director Grant Pickering receives 28,000 stock options - Stock Titan
Director Romano Kelly receives 28,000 LeonaBio (LONA) stock options at $9.54 - Stock Titan
LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) director awarded options on 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) grants CMO 350,000 options at $9.54 - Stock Titan
Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA) - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to general counsel - Stock Titan
LeonaBio (LONA) CFO awarded 300,000 stock options at $9.54 - Stock Titan
LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike - Stock Titan
Sentiment Recap: Should I invest in Athira Pharma Inc before earningsQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Market Outlook: What is the long term forecast for Athira Pharma Inc stockNew Guidance & Reliable Trade Execution Plans - baoquankhu1.vn
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Athira Pharma, Inc. (LONA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook - Investing.com
Athira Pharma, Inc. (ATHA) Competitors - Meyka
[EFFECT] LeonaBio, Inc. SEC Filing - Stock Titan
Performance Recap: What is the PEG ratio of Athira Pharma Inc2026 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
LeonaBio (NASDAQ: ATHA) registers 58.5M shares; warrants could yield $146M - Stock Titan
RSI Check: Is Athira Pharma Incs growth already priced in2026 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
LeonaBio (ATHA) clears resale of 5.5M warrant shares for Sermonix - Stock Titan
LeonaBio (NASDAQ: LONA) files resale registration for PIPE warrant holders - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
Income Plays: Can Athira Pharma Inc be recession proofEarnings Risk Report & Reliable Trade Execution Plans - baoquankhu1.vn
Aug Movers: Can Athira Pharma Inc expand into new markets2026 Market Trends & Weekly Market Pulse Alerts - baoquankhu1.vn
LeonaBio Reports 2025 Financial Results, Acquires Lasofoxifene License, and Advances Clinical Pipeline for Metastatic Breast Cancer and ALS 123 - Minichart
LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - Bitget
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
LeonaBio lines up $90M and a 2027 readout for breast cancer drug - Stock Titan
Momentum Shift: Can Athira Pharma Inc be recession proof2026 Pullback Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) - Defense World
What dividend growth rate does Athira Pharma Inc offer2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
LeonaBio shareholders approve equity plan and increase in authorized shares - Investing.com India
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
Published on: 2026-03-20 02:58:44 - baoquankhu1.vn
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.87%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):